CN111201241A - 用C5a活性抑制剂治疗炎性疾病 - Google Patents

用C5a活性抑制剂治疗炎性疾病 Download PDF

Info

Publication number
CN111201241A
CN111201241A CN201880041303.4A CN201880041303A CN111201241A CN 111201241 A CN111201241 A CN 111201241A CN 201880041303 A CN201880041303 A CN 201880041303A CN 111201241 A CN111201241 A CN 111201241A
Authority
CN
China
Prior art keywords
antibody
antigen
binding
binding fragment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880041303.4A
Other languages
English (en)
Chinese (zh)
Inventor
郭仁峰
尼尔斯·R·里德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of CN111201241A publication Critical patent/CN111201241A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
CN201880041303.4A 2017-06-23 2018-06-13 用C5a活性抑制剂治疗炎性疾病 Pending CN111201241A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17177657.8 2017-06-23
EP17177657 2017-06-23
EP17189938.8 2017-09-07
EP17189938 2017-09-07
PCT/EP2018/065676 WO2018234118A1 (en) 2017-06-23 2018-06-13 Treatment of inflammatory diseases with inhibitors of c5a activity

Publications (1)

Publication Number Publication Date
CN111201241A true CN111201241A (zh) 2020-05-26

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041303.4A Pending CN111201241A (zh) 2017-06-23 2018-06-13 用C5a活性抑制剂治疗炎性疾病

Country Status (10)

Country Link
EP (1) EP3642230A1 (https=)
JP (1) JP7502865B2 (https=)
KR (1) KR20200020727A (https=)
CN (1) CN111201241A (https=)
AU (1) AU2018286754A1 (https=)
CA (1) CA3066689C (https=)
IL (1) IL271074A (https=)
SG (1) SG11201912882QA (https=)
TW (1) TWI786132B (https=)
WO (1) WO2018234118A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364695A (zh) * 2020-06-24 2022-04-15 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
MA55285A (fr) * 2019-03-14 2022-01-19 Morphosys Ag Anticorps ciblant c5ar
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4126222A1 (en) * 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1604909A (zh) * 2001-10-17 2005-04-06 昆士兰大学 作为g蛋白－偶联受体拮抗剂的环肽
CN1997384A (zh) * 2004-03-26 2007-07-11 普罗米克斯有限公司 使用补体C5a受体调节剂治疗神经系统病症
CN105392803A (zh) * 2013-05-08 2016-03-09 诺和诺德股份有限公司 C5aR拮抗剂的用途
WO2016102877A1 (fr) * 2014-12-23 2016-06-30 Galderma Research & Development Nouveaux composés antagonistes des récepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies médiées par des chimiokines
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
CN111108118A (zh) * 2017-04-03 2020-05-05 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL3385384T3 (pl) 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
EP2049141A4 (en) 2006-07-21 2011-10-26 Promics Pty Ltd TREATMENT OF INTIMAL HYPERPLASIA AND ASSOCIATED DISEASES
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
CA3216595A1 (en) 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1604909A (zh) * 2001-10-17 2005-04-06 昆士兰大学 作为g蛋白－偶联受体拮抗剂的环肽
CN1847261A (zh) * 2001-10-17 2006-10-18 昆士兰大学 作为g蛋白－偶联受体拮抗剂的环肽
CN1997384A (zh) * 2004-03-26 2007-07-11 普罗米克斯有限公司 使用补体C5a受体调节剂治疗神经系统病症
CN105392803A (zh) * 2013-05-08 2016-03-09 诺和诺德股份有限公司 C5aR拮抗剂的用途
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
WO2016102877A1 (fr) * 2014-12-23 2016-06-30 Galderma Research & Development Nouveaux composés antagonistes des récepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies médiées par des chimiokines
CN111108118A (zh) * 2017-04-03 2020-05-05 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa", pages 1 - 2 *
AH-WENG A.等: "化脓性汗腺炎伴发坏疽性脓皮病", 世界核心医学期刊文摘·皮肤病学, vol. 2, no. 2, 28 February 2006 (2006-02-28), pages 46 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364695A (zh) * 2020-06-24 2022-04-15 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
CN114364695B (zh) * 2020-06-24 2024-07-12 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
US12534521B2 (en) 2020-06-24 2026-01-27 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing C5A and uses thereof

Also Published As

Publication number Publication date
TWI786132B (zh) 2022-12-11
SG11201912882QA (en) 2020-01-30
EP3642230A1 (en) 2020-04-29
CA3066689A1 (en) 2018-12-27
IL271074A (en) 2020-01-30
AU2018286754A1 (en) 2019-12-19
KR20200020727A (ko) 2020-02-26
JP7502865B2 (ja) 2024-06-19
TW201904611A (zh) 2019-02-01
WO2018234118A1 (en) 2018-12-27
JP2020524696A (ja) 2020-08-20
CA3066689C (en) 2024-01-16

Similar Documents

Publication Publication Date Title
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
US11273225B2 (en) Treatment of inflammatory diseases with inhibitors of C5a activity
TWI786132B (zh) 活性抑制劑於發炎性疾病之治療
TWI834025B (zh) 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
EP3220952B1 (en) Method of treating or preventing stroke
CN106132982A (zh) 用于治疗病毒性肺炎的C5a抑制剂
JP2023518884A (ja) コロナウイルス感染の処置のためのＣ５ａのインヒビター
US20220308056A1 (en) Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
US20250206838A1 (en) Therapeutic inhibition of cd38 to treat hidradenitis suppurativa
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200526